Ruben Abagyan is a Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, and Molsoft LLC founder.
After graduating MIPT summa cum laude and receiving his PhD in Biophysics from MSU, he spent 5 years at the European Institute of Molecular Biology in Heidelberg, Germany, as a staff scientist. Ruben Abagyan moved to New York University as an Associate Professor of Biochemistry and Mathematics in NYU Medical School and Courant Institute of Mathematics, and the director of Computational Chemistry and IT at the NYU Skirball Institute; founded Molsoft, LLC; became Director of Computational Chemistry at the Novartis Institute of Functional Genomics in San Diego, and spent 10 years as a tenured Professor at the Scripps Research Institute before joining UCSD. Ruben Abagyan published 300 articles and chapters that have been cited 41,000 times, achieving an H-index of 97, and i10-index of 306. He has been serving on high profile international review and advisory panels in the EU, UK, Switzerland, Hong Kong, and on several boards of directors of biotech startups. He received CapCure awards, UCSD teaching excellence awards, top 1% most performing and cited faculty, and Princess Diana award and medal.
In 2023 his project "DARTS: Discovery of New Drug Targets and First-in-class Chemical Modulators: from Diverse 3D-AI data to Leads" in Armenia was funded by FAST.